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Mutational analyses of ORFs within the vraSR operon and their
roles in the cell wall stress response of Staphylococcus aureus
Abstract
Exposure of Staphylococcus aureus to a broad range of cell wall-damaging agents, triggers the induction
of a cell wall stress stimulon (CWSS), controlled by the VraSR two-component system. The vraSR
genes form part of the four-cistronic autoregulatory operon, orf1-yvqF-vraS-vraR. Markerless
inactivation of each of the genes within this operon revealed that orf1 played no observable role in
CWSS induction and had no influence on resistance phenotypes for any of the cell envelope
stress-inducing agents tested. The remaining three genes were all essential for induction of the CWSS
and mutants showed varying degrees of increased susceptibility to cell wall active antibiotics. Therefore,
the role of YvqF in S. aureus appears to be opposite to that in other Gram-positive bacteria, where YvqF
homologs have all been shown to inhibit signal transduction. This role, as an activator rather than
repressor of signal transduction, corresponds well with resistance phenotypes of ΔYvqF mutants, which
were similar to those of ΔVraR mutants in which CWSS induction was also completely abolished.
Resistance profiles of ΔVraS mutants differed phenotypically from those of ΔYvqF and ΔVraR mutants
on many non-ß-lactam antibiotics. ΔVraS mutants still became more susceptible than wild type strains at
low antibiotic concentrations, but retained larger subpopulations able to grow on higher antibiotic
concentrations than ΔYvqF and ΔVraR mutants. Subpopulations of ΔVraS mutants could grow on even
higher glycopeptide concentrations than wild type strains. Expression of a highly sensitive
CWSS-luciferase reporter gene fusion, was up to 2.6-fold higher in a ΔVraS than a ΔVraR mutant,
which could be linked to differences in their respective antibiotic resistance phenotypes. Bacterial
two-hybrid analysis indicated that the integral membrane protein YvqF interacted directly with VraS but
not VraR, suggesting that it plays an essential role in sensing the as yet unknown trigger of CWSS
induction.
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ABSTRACT 1 
Exposure of Staphylococcus aureus to a broad range of cell wall-damaging agents, 2 
triggers the induction of a cell wall stress stimulon (CWSS), controlled by the VraSR 3 
two-component system. The vraSR genes form part of the four-cistronic 4 
autoregulatory operon, orf1-yvqF-vraS-vraR. Markerless inactivation of each of the 5 
genes within this operon revealed that orf1 played no observable role in CWSS 6 
induction and had no influence on resistance phenotypes for any of the cell envelope 7 
stress-inducing agents tested. The remaining three genes were all essential for 8 
induction of the CWSS and mutants showed varying degrees of increased 9 
susceptibility to cell wall active antibiotics. Therefore, the role of YvqF in S. aureus 10 
appears to be opposite to that in other Gram-positive bacteria, where YvqF homologs 11 
have all been shown to inhibit signal transduction. This role, as an activator rather 12 
than repressor of signal transduction, corresponds well with resistance phenotypes of 13 
∆YvqF mutants, which were similar to those of ∆VraR mutants in which CWSS 14 
induction was also completely abolished. Resistance profiles of ∆VraS mutants 15 
differed phenotypically from those of ∆YvqF and ∆VraR mutants on many non-ß-16 
lactam antibiotics. ∆VraS mutants still became more susceptible than wild type 17 
strains at low antibiotic concentrations, but retained larger subpopulations able to 18 
grow on higher antibiotic concentrations than ∆YvqF and ∆VraR mutants. 19 
Subpopulations of ∆VraS mutants could grow on even higher glycopeptide 20 
concentrations than wild type strains. Expression of a highly sensitive CWSS-21 
luciferase reporter gene fusion, was up to 2.6-fold higher in a ∆VraS than a ∆VraR 22 
mutant, which could be linked to differences in their respective antibiotic resistance 23 
phenotypes. Bacterial two-hybrid analysis indicated that the integral membrane 24 
protein YvqF interacted directly with VraS but not VraR, suggesting that it plays an 25 
essential role in sensing the as yet unknown trigger of CWSS induction.  26 
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INTRODUCTION 27 
The bacterial cell envelope is a major target for antimicrobial agents, most of which 28 
act by blocking or disrupting peptidoglycan synthesis (7). Integrity of the cell 29 
envelope is essential in Staphylococcus aureus for survival and pathogenicity, as it 30 
not only protects cells against environmental stresses, but also modulates 31 
colonization, virulence and antimicrobial resistance. Structural rigidity of the 32 
staphylococcal cell envelope is provided by a multi-layered and highly cross-linked 33 
peptidoglycan cell wall, surrounding the cytoplasmic membrane. Accessory features 34 
governing physicochemical properties of the cell surface include, wall- and lipo-35 
teichoic acids, membrane-associated and peptidoglycan-anchored proteins and 36 
extracellular polysaccharide matrices. Bacteria rely on sensory elements within their 37 
cell envelope to trigger adaptive responses to wide-ranging environmental conditions. 38 
A large family of such signal transducers are the two-component systems (TCS), 39 
consisting of membrane-anchored sensor kinases that respond to environmental 40 
signals and activate cognate response regulators, to induce or repress specific sets 41 
of target genes.  42 
Many Gram-positive bacteria contain TCS regulatory systems that respond to cell 43 
envelope damage or disruption of cell wall synthesis and trigger protective cell 44 
envelope stress responses (reviewed in (19)). Exposure of S. aureus to diverse cell 45 
wall-targeting antibiotics, or depletion of essential cell wall synthesis enzymes, have 46 
been shown to induce the VraSR TCS, which controls a large VraSR-dependent cell 47 
wall stress stimulon (CWSS) (14, 27, 43, 47). Induction of the VraSR-dependent 48 
CWSS in S. aureus is thought to protect against cell envelope damage by enhancing 49 
peptidoglycan synthesis, through induction of genes including: pbp2, the only 50 
bifunctional staphylococcal penicillin binding protein (PBP) with both transglycosylase 51 
and transpeptidase activity (39), murZ (a redundant MurA isozyme (5)), sgtB (a 52 
soluble transglycosylase (50)) and fmtA (an accessory PBP with low affinity for beta-53 
lactams (13)) (27, 30, 47). The CWSS of S. aureus also contains several genes of 54 
currently unknown function or unknown significance to the stress response. 55 
Upregulation of the VraSR-dependent CWSS has been linked to increased ß-lactam 56 
and glycopeptide resistance phenotypes in several clinical S. aureus (23, 24, 28, 30). 57 
The VraSR-TCS shares homology with other well studied Gram-positive TCS 58 
modulators of cell wall stress, such as LiaRS from Bacillus subtilis, Streptococcus 59 
pneumoniae and Streptococcus mutans and CesSR from Lactococcus sp. (12, 20, 60 
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29, 45). Although these homologous systems have all been shown to respond to 61 
similar signals and function in similar ways, there is little conservation in the size of 62 
their regulons and the types of genes they control, indicating that the respective 63 
stress responses mounted are highly genera- or species-specific, probably in 64 
response to niche-specific stresses and required adaptive responses. The exact 65 
signal sensed by these TCS is unknown and while there is significant overlap in the 66 
types of antibiotics or enzymes able to induce signal transduction, there are also 67 
organism-specific differences, suggesting that TCS are activated by a signal resulting 68 
from general cell wall damage and/or inhibition of cell wall synthesis (19).   69 
TCS genes belonging to this family are all co-transcribed with a third gene, 70 
homologous to liaF in B. subtilis, on a single autoregulatory transcript (19). In B. 71 
subtilis and S. mutans, the membrane anchored LiaF protein, was shown to repress 72 
LiaSR-dependent signal transduction under normal growth conditions (20, 45). 73 
Because of the integral part LiaF plays in LiaSR signal transduction and the identical 74 
resistance phenotypes of liaF and liaR mutants in S. mutans, it was proposed that 75 
these loci are in fact three-component systems (e.g. LiaFSR). In S. aureus, little is 76 
known about the liaF homolog, yvqF, which is located directly upstream of vraS in the 77 
four gene operon, orf1-yvqF-vraS-vraR. However, step selection of a methicillin 78 
resistant S. aureus (MRSA) first on inhibitory concentrations of imipenem then 79 
teicoplanin, was shown to select for point mutations in either yvqF or vraS at a high 80 
frequency; and some clinical glycopeptide intermediate-resistant S. aureus (GISA) 81 
isolates from diverse geographical locations were found to have different point 82 
mutations in either yvqF or vraS. However, no strains analysed had mutations in both 83 
loci, indicating that mutation of both genes would not confer a further resistance 84 
advantage (23).  85 
Inactivation of VraSR decreases resistance to most VraSR-inducing cell wall-86 
damaging agents, indicating that the CWSS controlled by this TCS is essential for the 87 
expression of several different resistance phenotypes. Conversely, a specific point 88 
mutation in VraS, activating signal transduction in the absence of antibiotic induction, 89 
was shown to contribute to increased teicoplanin resistance in some clinical GISA 90 
(24). No specific relationship has yet been found between any of the yvqF point 91 
mutations found in clinical S. aureus or generated by in vitro selection on 92 
imipenem/teicoplanin and the resistance phenotypes of the strains analysed (23).  93 
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In this study, we introduced non-polar mutations into each of the four open reading 94 
frames (ORFs) of the orf1-yvqF-vraS-vraR operon and compared their impacts on 95 
induction of the CWSS and on resistance phenotypes to cell wall active antibiotics 96 
targeting several different steps of the cell wall synthesis pathway, in both an MRSA 97 
and a near-isogenic methicillin susceptible S. aureus (MSSA) strain background. We 98 
also analysed protein-protein interactions between YvqF, VraS and VraR, using a 99 
bacterial two-hybrid (BTH) system developed by Karimova et al. (21, 22), which was 100 
previously used to successfully show protein-protein interactions in S. aureus (40) 101 
and between members of TCS (46). 102 
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MATERIALS AND METHODS 103 
 104 
Bacterial strains and growth conditions. 105 
Strains and plasmids used in this study are listed in Table 1. Bacteria were grown on 106 
sheep-blood or Luria Bertani (LB) agar plates, and liquid cultures were grown in LB 107 
with shaking at 180 rpm at a medium:flask volume ratio of 1:4. All OD measurements 108 
given were taken at OD 600 nm. Media were supplemented with the following 109 
antibiotics when appropriate: 25 µg/ml or 50 µg/ml of kanamycin, 50 µg/ml or 100 110 
µg/ml of ampicillin, 10 µg/ml of tetracycline or 10 µg/ml of chloramphenicol. Phage 111 
80α was used for transduction.  112 
 113 
Construction of pKOR1 markerless mutations. 114 
The pKOR1 system created by Bae et al. (1), was used to construct a markerless 115 
deletion of orf1 and to truncate YvqF, VraS and VraR proteins by inserting two stop 116 
codons in-frame into the beginning of their respective ORFs (Fig. 1). Primers used for 117 
plasmid construction are listed in Table 2. For orf1 deletion, upstream and 118 
downstream genomic regions flanking orf1 were amplified using primer pairs attB1-119 
yvqF.upF/BamHI-orf1.upR and BamHI-orf1.downF/attB2-yvqF.downR, respectively. 120 
Flanking regions were digested with BamHI, ligated together and recombined into 121 
pKOR1 using Gatweway BP Clonase II enzyme mix (Invitrogen). To create pKOR1 122 
constructs that would insert an XhoI site and two in-frame stop codons into the 123 
beginning of yvqF, vraS and vraR ORFs, regions directly upstream and containing 124 
the first 2-5 codons of the ORFs followed by an XhoI site, were amplified using the 125 
primer pairs attB1-yvqF.upF/XhoI-yvqF.upR, attB1-yvqF-upF/XhoI-vraS.upR and 126 
attB1-vraR.upF/XhoI-vraR.upR, respectively. Adjacent regions, containing the 127 
remainder of the yvqF, vraS or vraR ORFs, preceded by two stop codons and an 128 
XhoI site, were amplified using primer pairs XhoI-stop-yvqF.downF/attB2-129 
yvqF.downR, XhoI-stop-vraS.downF/attB2-yvqF.downR and XhoI-stop-130 
vraR.downF/attB2-vraR.downR, respectively. Amplicon pairs were digested with 131 
XhoI, ligated together and recombined into pKOR1. Mutations were introduced into 132 
the genomes of S. aureus strains RN4220 and BB270, using the inducible counter 133 
selection protocol described by Bae et al. (1), and confirmed by PCR and sequencing 134 
across the deleted or genetically manipulated region. Sequence analysis of the entire 135 
vra operon region of the yvqF mutant was also performed to ensure that no additional 136 
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mutations had been introduced. All mutants were also screened by pulsed field gel 137 
electrophoresis (PFGE) (48), to confirm that no additional major genomic 138 
rearrangements had occurred (data not shown).  139 
 140 
vra operon complementation. 141 
The entire orf1-yvqF-vraS-vraR operon, including the published promoter region (3, 142 
52) and predicted transcriptional terminator (http://cmr.jcvi.org/), was amplified from 143 
S. aureus COL, using primers vra.compF and vra.compR (Table 2), and cloned into 144 
pAW17 to create plasmid pvra. To demonstrate that mutation of yvqF introduced no 145 
polar effects on the downstream vraS and vraR genes, complementation plasmids 146 
pvra∆YvqF and pvra∆VraR were also constructed. These plasmids contained vra 147 
operon inserts from BB270∆YvqF and BB270∆VraR, amplified using primers 148 
vra.compF and vra.compR.  149 
 150 
Antibiotic resistance tests. 151 
Several different techniques were employed to quantitatively and qualitatively 152 
compare resistance phenotypes to fifteen different antibiotics, targeting various 153 
different cell wall structures or stages of cell wall synthesis (Fig. 2). Minimum 154 
inhibitory concentrations (MIC) of antibiotics were determined by Etest (AB-Biodisk), 155 
according to the manufacturer’s instructions. Glycopeptide MICs were also 156 
determined using the macro-Etest method, recommended for its high specificity and 157 
sensitivity in identifying differences in glycopeptide resistance levels (49). Macro-158 
Etest were performed on brain heart infusion (BHI) (BBL) agar swabbed with 2.0 159 
McFarland suspensions and incubated at 35 °C for 48 h. Broth microdilutions were 160 
performed according to CLSI guidelines (9).  161 
Antibiotic resistance profiles were compared by population analysis profile (PAP), 162 
whereby appropriate dilutions of an overnight culture, ranging from 100 to 10-8, were 163 
plated on increasing concentrations of oxacillin (0.5-512 µg/ml) (InfectoPharm), 164 
teicoplanin (0.0625-8 µg/ml) (Hoechst Marion Roussel), vancomycin (0-8 µg/ml) (Eli 165 
Lilly & Company), flavomycin (0-8 µg/ml) (BC Biochemie GmbH) or daptomycin (0-2 166 
µg/ml) (Cubist Pharmaceuticals, Inc.) and incubated at 35°C. Colony forming units 167 
per ml (cfu/ml) were determined after 48 h. Daptomycin plates were supplemented 168 
with 50 µg/ml of CaCl2, corresponding to ~27 µg/ml Ca2+, which in addition to the ~20 169 
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µg/ml Ca2+ from the Difco agar (BD Biosciences) present in the plates gave a final 170 
concentration of ~47 µg/ml Ca2+. 171 
Gradient plates were used to compare resistance phenotypes for lysostaphin (Ambi), 172 
ramoplanin (Sigma), ceftobiprole (Johnson & Johnson Pharmaceutical Research & 173 
Development), D-cycloserine (Sigma) and triton X-100 (Fluka). Bacterial suspensions 174 
of 2.0 McFarland were used to enhance visualisation of population heterogeneity. 175 
The suspensions were swabbed across agar plates containing appropriate antibiotic 176 
concentration gradients and plates were incubated at 35°C for 24-48 h.   177 
Relative resistance levels of strains containing the empty plasmid pAW17 and the 178 
complementing plasmids pvra, pvra∆YvqF or pvra∆VraR were also compared by 179 
gradient plate, whereby bacterial suspensions of 0.5 McFarland were swabbed 180 
across agar plates containing a teicoplanin gradient of 0-4 µg/ml. Plates for 181 
complementation comparisons were supplemented with kanamycin (50 µg/ml) to 182 
ensure plasmid maintenance.  183 
 184 
Northern blots. 185 
Northern blots were performed as previously described (32). Overnight cultures were 186 
diluted to OD 0.05 in fresh prewarmed LB containing kanamycin (50 µg/ml) and 187 
grown to OD 0.5. Uninduced samples were harvested and the remaining culture was 188 
induced with vancomycin (10 µg/ml) for 30 min before induced samples were 189 
collected. Total RNA was extracted as described by Cheung et al. (8). RNA samples 190 
(8 µg) were separated in a 1.5 % agarose-20 mM guanidine thiocyanate gel in 1 x 191 
TBE buffer (16). Digoxigenin (DIG) labelled-probes were amplified using the PCR 192 
DIG Probe synthesis kit (Roche), with primer pairs listed in Table 2. All Northern blots 193 
were repeated at least two times, using independently isolated RNA samples.  194 
 195 
Luciferase reporter-gene fusion assay. 196 
The promoter region of sas016, which corresponds to ORF SACOL0625 from S. 197 
aureus COL (accession: NC_002951), was amplified using primers SAS016.lucF and 198 
SAS016.lucR (Table 2), digested with Asp718 and NcoI and ligated directly upstream 199 
of the promoterless luciferase (luc+) gene in vector pSP-luc+ (Promega). A fragment 200 
containing the sas016 promoter-luc+ translational fusion was then excised with 201 
Asp718 and EcoR1 and cloned into the E. coli-S. aureus shuttle vector pBUS1. The 202 
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fusion plasmid, psas016p-luc+ was transformed into S. aureus RN4220 then 203 
transduced into further strains. 204 
For induction assays, two identical culture broths were inoculated with an overnight 205 
culture to an OD of 0.05. Cultures were grown to between OD 0.4-0.5 and then split 206 
into two flasks; one was left uninduced and the other induced with vancomycin (10 207 
µg/ml). After 30 min, samples were collected from both uninduced and induced 208 
cultures. To determine luciferase activity over growth, three separate culture broths 209 
for each mutant were inoculated with an overnight culture to an OD of 0.05 and 210 
grown for 9 h. Samples were collected at 1.5, 3, 4.5, 6, 7.5 and 9 h time points and  211 
OD values were recorded. Samples were harvested by centrifugation and pellets 212 
were frozen at -20 °C. For luciferase activity measurements, pellets were 213 
resuspended in PBS to an OD of 10 and aliquots mixed with equal amounts of 214 
Luciferase Assay System substrate (Promega). Luminescence was measured for 15 215 
s after a delay of 3 s on a Turner Designs TD-20/20 luminometer (Promega). 216 
 217 
Bacterial two-hybrid (BTH) plasmid construction and interaction screening. 218 
The yvqF, vraS and vraR gene sequences were amplified from S. aureus COL 219 
genomic DNA and cloned into four BTH vectors to create N-terminal (pKT25 and 220 
pUT18C) and C-terminal (pKNT25 and pUT18) protein fusions to the T25 or T18 221 
domains of Bordetella pertussis CyaA (21, 22). To create in-frame fusions, two 222 
different inserts were amplified for each gene. Inserts amplified with x.pKT25F and 223 
x.BTHR primers were cloned into pKT25, whereas inserts amplified with x.pUT18CF 224 
and x.BTHR primers were cloned into pUT18C, pUT18 and pKNT25 vectors.  225 
Combinations of constructs were then transformed into the reporter strain E. coli 226 
BTH101 and co-transformants were selected on LB agar containing ampicillin (100 227 
µg/ml), kanamycin (25 µg/ml), Xgal (40 µg/ml) and IPTG (24 µg/ml) and on M63 228 
minimal agar containing lactose as a sole carbon source (22) and supplemented with 229 
ampicillin (50 µg/ml), kanamycin (25 µg/ml), Xgal (40 µg/ml) and IPTG (24 µg/ml). 230 
Co-transformants were then spotted onto LB or M63 agar containing Xgal, IPTG, 231 
amplicillin and kanamycin. Interactions were also quantified by performing ONPG (o-232 
nitrophenyl-ß-D-galactopyranoside) (Sigma) cleavage assays to measure ß-233 
galactosidase activity, according to the standard protocol (34).  234 
Co-transformants containing the empty vectors pKT25 and pUT18C were used as a 235 
negative control. As a positive control, plasmids pKT25-sigB and pUT18C-rsbW, 236 
  Page 10 of 30 
containing the alternalte sigma factor SigB and its anti-sigma factor RsbW, from S. 237 
aureus COL, were constructed and co-transformed into E. coli BTH101. These two 238 
proteins were chosen as they have been shown to interact strongly in S. aureus (35).  239 
  Page 11 of 30 
RESULTS 240 
 241 
Antibiotic resistance profiles of orf1, yvqF, vraS and vraR mutants.  242 
MIC comparisons: MICs were measured to determine the impact of orf1, yvqF, vraS 243 
and vraR mutations on antibiotic resistance levels in the near isogenic MSSA 244 
(RN4220) and MRSA (BB270) strains (Table 3). Deletion of orf1 had no noticeable 245 
effect on antibiotic resistance levels in either strain background. Meanwhile 246 
inactivation of yvqF, vraS and vraR all generally decreased resistance levels, 247 
although ß-lactam resistances (oxacillin, cefoxitin and imipenem) were only affected 248 
in the MRSA background.  249 
Strain-dependent differences between RN4220 and BB270 mutants were also seen 250 
in resistance levels to some non-ß-lactam antibiotics including fosfomycin, 251 
daptomycin, tunicamycin and bacitracin. ∆YvqF, ∆VraS and ∆VraR mutations 252 
influenced resistance levels to varying degrees, with huge MIC decreases for 253 
teicoplanin (up to 30 fold), more moderate decreases (2-6 fold) for bacitracin, 254 
fosfomycin and the ß-lactam antibiotics in the BB270 background and only marginal 255 
effects (≤ 2-fold) on daptomycin and vancomycin resistances.  256 
In general, yvqF and vraR mutants gave highly comparable MIC readings indicating 257 
that YvqF was as essential as VraR for protecting against cell wall damage. MICs of 258 
∆VraS mutants were similar to those of ∆YvqF and ∆VraR mutants for some 259 
antibiotics (oxacillin, cefoxitin, bacitracin and tunicamycin), but were up to several-260 
fold higher for others (teicoplanin, vancomycin, fosfomycin and daptomycin).  261 
 262 
PAP: For more indepth comparisons of resistance profiles, BB270 and its orf1, yvqF, 263 
vraS and vraR mutants were also analysed by PAP on selected antibiotics (Fig. 3A). 264 
Profiles of BB270∆orf1 were identical to wild type BB270 on all antibiotics tested. 265 
Teicoplanin PAPs showed severe changes in resistance profiles in ∆YvqF, ∆VraS 266 
and ∆VraR mutants, with an immediate drop of 2-4-log in cfu in all mutants at 0.0625 267 
µg/ml of teicoplanin, while wild type and orf1 mutants grew on concentrations up to 268 
0.5 µg/ml before cfu began to decrease. Profiles of ∆YvqF, ∆VraS and ∆VraR 269 
mutants also showed varying levels of resistance heterogeneity. ∆YvqF and ∆VraR 270 
mutant curves were almost identical and showed that both strains had become highly 271 
susceptible, retaining only a small sub-population able to grow at concentrations 272 
between 0.0625 and 8 µg/ml. The ∆VraS mutant showed a markedly different 273 
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phenotype; even though cfu/ml still dropped immediately, at 0.0625 µg/ml of 274 
teicoplanin, the ∆VraS mutant retained a much larger subpopulation able to grow on 275 
higher teicoplanin concentrations. Between 1 and 8 µg/ml, the surviving 276 
subpopulation of the ∆VraS mutant was even higher, by up to 2-log, than that of the 277 
wild type.  278 
Resistance profiles of all strains displayed the same trends on vancomycin, although 279 
overall differences in resistance were much smaller and seen over a much narrower 280 
range of vancomycin concentrations (0.5-4 µg/ml). The resistant subpopulation of the 281 
VraS mutant was once again greater than that of the wild type at concentrations over 282 
1 µg/ml. The ∆VraS mutant also retained a much larger resistant subpopulation than 283 
the ∆YvqF and ∆VraR mutants on flavomycin, although it never became more 284 
resistant than the wild type.  285 
Conversely, ∆YvqF, ∆VraS and ∆VraR mutants all had identical resistance 286 
phenotypes on oxacillin, with all three mutants becoming much more heterogeneous 287 
at oxacillin concentrations > 16 µg/ml, while the wild type and orf1 mutants remained 288 
homogeneously resistant until grown on concentrations of > 128  µg/ml.  289 
Daptomycin PAPs showed only small differences, but gave a clearer picture of 290 
resistance phenotypes than the Etest readings. ∆YvqF and ∆VraR mutants were 291 
more susceptible than the other three strains at daptomycin concentrations > 0.25 292 
µg/ml. The ∆VraS mutant, once again appeared to be more resistant than all other 293 
strains at higher daptomycin concentrations, although only marginally. 294 
 295 
Gradient plate comparisons: Resistance phenotypes of RN4220 and BB270 strain 296 
sets were also compared on lysostaphin, ramoplanin, D-cycloserine, ceftobiprole, 297 
and triton X-100 gradient plates (Fig. 3B). Triton X-100 gradient plates showed that 298 
yvqF/vraS/vraR mutants were all much more susceptible than the wild type and all 299 
displayed heterogeneous resistance profiles, although the ∆VraS mutant appeared to 300 
have a larger subpopulation able to grow on higher concentrations of triton X-100 301 
than ∆YvqF and ∆VraR. All three yvqF/vraS/vraR mutants had indistinguishable  302 
resistance phenotypes on ramoplanin and D-cycloserine, although ramoplanin 303 
resistance was decreased to a much greater extent than D-cycloserine resistance, 304 
where observable differences were very small but highly reproducible. BB270 ∆YvqF, 305 
∆VraS and ∆VraR mutants were also slightly more susceptible to ceftobiprole, but as 306 
with other ß-lactam-family antibiotics tested, none of the mutations affected 307 
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resistance in RN4220. BB270-derived strains were also more intrinsically resistant 308 
than their RN4220 counterparts to triton X-100 and D-cycloserine, but not to 309 
ramoplanin or lysostaphin. Resistance levels to lysostaphin did not appear to be 310 
affected by any of the vra operon mutations in either strain background.   311 
  312 
Complementation. 313 
Gradient plates comparing teicoplanin resistance levels of BB270, BB270∆orf1, 314 
BB270∆YvqF, BB270∆VraS and BB270∆VraR, containing either the empty control 315 
plasmid pAW17 or plasmid pvra (Fig. 4A), showed that yvqF, vraS and vraR mutants 316 
could all be complemented by introducing the orf1-yvqF-vraS-vraR operon in trans.  317 
To exclude the possibility that polar effects were introduced during mutant 318 
construction a further two complementing plasmids, containing the vra operons 319 
amplified from BB270∆YvqF or BB270∆VraR, were created (Fig. 4B). BB270∆VraS 320 
and BB270∆VraR could both be complemented by pvra∆YvqF, indicating that vraS 321 
and vraR genes were both still functional in BB270∆YvqF. Visual comparison of 322 
growth on gradient plates indicated that pvra and pvra∆VraR both complemented 323 
growth of BB270∆VraS to wild type levels. However, when complemented with 324 
pvra∆YvqF, growth of BB270∆VraS appeared fainter, indicating that although 325 
resistance was clearly complemented, wild type growth was not fully restored. Both 326 
BB270∆YvqF and BB270∆VraS could also be complemented by pvra∆VraR, further 327 
suggesting that the introduced mutations had not created polar effects on other 328 
genes within this operon (Fig. 4C).  329 
 330 
CWSS induction in orf1, yvqF, vraS and vraR mutants. 331 
Induction of CWSS genes in BB270, BB270∆orf1, BB270∆YvqF, BB270∆VraS and 332 
BB270∆VraR, was compared by Northern blotting. Genes used as probes included 333 
sas016, because it is highly induced by cell wall active antibiotics (33), and vraR, 334 
because the orf1-yvqF-vraS-vraR transcript is autoregulated and transcription should 335 
not be disrupted in the ∆VraR mutant. Both transcripts were highly induced in wild 336 
type BB270 and the orf1 mutant, but no induction was visible in the ∆YvqF, ∆VraS or 337 
∆VraR mutants (Fig. 5A). 338 
Luciferase activity from plasmid psas016p-luc+, was also measured in both 339 
uninduced and vancomycin-induced cultures of BB270 and its four mutants (Fig. 5B). 340 
Results confirmed that there was no induction in ∆YvqF, ∆VraS and ∆VraR mutants 341 
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and showed that expression levels in the absence of induction were much lower in 342 
these three strains than in the wild type. OD values, both before and after induction, 343 
were very similar for all five strains, indicating that there were no significant 344 
differences in growth phenotypes (data not shown). 345 
Luciferase activity measurements over growth showed that all three mutants had 346 
subtle but highly reproducible differences in sas016 promoter activity (Fig. 5C). 347 
Luciferase activity was lowest in the ∆VraR mutant, throughout all sampling points. 348 
Activity in the ∆YvqF mutant ranged between 1.1- and 1.7-fold higher than in the 349 
∆VraR mutant; while in the ∆VraS mutant it ranged from 1.5- to 2.6-fold higher. 350 
 351 
BTH protein-protein interactions. 352 
The BTH system was used to analyse protein-protein interactions between YvqF, 353 
VraS and VraR (Fig. 6A and B). Genes, yvqF, vraS and vraR, were cloned into all 354 
four BTH vectors, however restriction digest profiles of pKNT25 (X-T25) constructs 355 
containing yvqF or vraS suggested that these clones were unstable and prone to 356 
frequent rearrangements (data not shown) and they were subsequently omitted from 357 
the study. Restriction profiles of the remaining ten constructs appeared stable and 358 
pairs of these plasmids were co-transformed into the reporter strain, E. coli BTH101.  359 
All co-transformations were repeated at least four times, using independently isolated 360 
plasmid constructs. Fig. 6C shows the phenotypes of three representative clones 361 
from each co-transformation, replica-plated onto minimal media containing lactose 362 
and Xgal. Levels of ß-galactosidase activity in each of the co-transformants were 363 
also measured to compare relative interaction strengths against negative and 364 
positive controls (Fig. 6D).  365 
Positive interactions between T25-VraS and both T18-VraS and VraS-T18 fusion 366 
clones, were consistent with the dimeric structure of sensor histidine kinases (2, 46) 367 
and indicated that all plasmids containing vraS functioned correctly in this system. 368 
Positive interactions resulted from three of four combinations of the YvqF and VraS 369 
plasmids suggesting a positive interaction between these two proteins. The pairing of 370 
T25-VraS and YvqF-T18 clones consistently gave negative results, which could be 371 
due to a genuine lack of interaction or arise as a false negative, due to the orientation 372 
of fusion-protein domains sterically hindering the interaction.  373 
All interactions between YvqF and VraR were negative, with ß-galactosidase levels in 374 
the same range as the negative control. The positive interaction between T25-YvqF 375 
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and YvqF-T18 clones suggested that YvqF could dimerize, although this was not 376 
supported in co-transformants containing T25-YvqF and T18-YvqF fusions.  377 
Remaining combinations, including VraR dimerization and VraS-VraR interaction 378 
gave heterogenous results, with interactions arising from some plasmid combinations 379 
and not others. However, interactions between these proteins, including the signal 380 
transduction cascade between VraS and VraR and the dimerization of VraR when 381 
phosphorylated by VraS or by acetyl phosphate in vitro, have already been 382 
thoroughly described (2, 3). 383 
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DISCUSSION 384 
VraSR-controlled CWSS induction is the major defence mounted by S. aureus in 385 
response to cell wall damage and provides varying levels of intrinsic 386 
resistance/tolerance to cell wall-targeting antibiotics. The importance of this stress 387 
response in S. aureus appears to be reflected in the relatively large size of the 388 
CWSS and its induction by all classes of cell wall active antibiotics (27, 36, 38, 42, 389 
44, 47). Homologous, LiaFSR-controlled CWSS from diverse species, including B. 390 
subtilis and the naturally competent S. pneumoniae, tend to be much smaller and 391 
only induced by antibiotics interacting directly with lipid II and/or specific murein 392 
hydrolases (12, 20, 45). The CWSS’s are perhaps more specialized in these bacteria 393 
due to the presence of additional regulatory mechanisms, such as the multiple cell 394 
envelope stress-responsive ECF sigma factors in B. subtilis and the production of the 395 
ComM immunity protein during competence in S. pneumoniae (12, 19). These extra 396 
layers of cell envelope stress response systems may have diminished the importance 397 
and/or narrowed the scope of the LiaFSR-dependent CWSS in these bacteria (19, 398 
51).  399 
This study investigated the roles of the individual genes within the of1-yvqF-vraS-400 
vraR operon on CWSS induction and resistance to cell wall-active antibiotics. orf1 401 
mutants were phenotypically identical to their respective wild type parent strains, 402 
indicating that Orf1 plays no role in CWSS induction. Analyses of the remaining 403 
mutants identified similarities, but also key differences, between the VraSR signal 404 
transduction system in S. aureus and the corresponding LiaFSR systems of B. 405 
subtilis, S. pneumoniae and S. mutans and the CesRS system of lactococci.     406 
The most striking difference was that YvqF was essential for both CWSS induction 407 
and CWSS-mediated antibiotic tolerance in S. aureus. The homologous, LiaF, protein 408 
from B. subtilis and S. mutans represses LiaSR signal transduction, with liaF deletion 409 
leading to constitutive expression of CWSS genes in the absence of an inducing 410 
signal (12, 20, 45). Mutation of yvqF, however, abolished CWSS induction in S. 411 
aureus.  412 
Inactivation of yvqF and vraR had almost identical effects on resistance phenotypes 413 
to all antibiotics tested. MICs of vraS mutants, however, were often higher than those 414 
of yvqF/vraR mutants. These phenotypes correlated with those published for S. 415 
mutans, whereby deletion of liaF and liaR both decreased resistance to lipid II-416 
interacting antibiotics to comparable levels, while liaS mutants were generally slightly 417 
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more antibiotic tolerant (45). Disparate results regarding the effects of LiaFSR-418 
inactivation on resistance phenotypes in S. mutans have been reported (45, 53) and 419 
were attributed to the methods used for resistance determination, with some methods 420 
such as disk tests giving less sensitive results than comparisons of MIC and 421 
minimum bacteriocidal concentration (MBC) by broth microdilution (45).  422 
In this study, resistance phenotypes were compared using several different methods. 423 
MIC determination enabled quantification of the impact of vra operon mutants on 424 
resistance levels, while PAP analysis and gradient plate comparisons enabled a 425 
more in-depth comparison of population resistance heterogeneity and the 426 
identification of subtle differences in resistance levels. PAP results confirmed that 427 
∆VraS mutants were less susceptible to glycopeptides than ∆YvqF/∆VraR mutants. 428 
Resistance profiles also showed that while ∆VraS mutants were much more 429 
susceptible than wild type strains at low antibiotic concentrations, they contained a 430 
subpopulation that was able to grow on higher glycopeptide concentrations than the 431 
wild type, indicating that vraS inactivation may actually increase tolerance to 432 
glycopeptides. ∆VraS mutants also showed greater tolerance than ∆YvqF/∆VraR 433 
mutants to several other antibiotics, including flavomycin, fosfomycin, daptomycin 434 
and the detergent triton X-100. However with the exception of daptomycin, ∆VraS 435 
mutants were not able to grow on higher antibiotic concentrations than the wild type 436 
for any of these antibiotics. No vraS-mutant specific phenotype was detected on ß-437 
lactams, ramoplanin or D-cycloserine, as ∆YvqF/∆VraS/∆VraR mutants all displayed 438 
near identical resistance phenotypes by PAP or gradient plate comparison.  439 
Decreased resistance to ß-lactams, including ceftobiprole, was only detected in 440 
BB270 (MRSA) mutants and not in RN4220 (MSSA) mutants, indicating that the 441 
CWSS only contributes to mecA-mediated resistance and not intrinsic ß-lactam 442 
tolerance. In BB270 oxacillin resistance levels decreased 8-fold, consistent with 443 
reported fold-decreases for vraS or vraSR mutants of other MRSA (6, 27). In some 444 
clinical, community-acquired MRSA, VraSR-inactivation decreases MICs to below 445 
susceptible breakpoint levels (6), however, in highly resistant strains such as BB270 446 
the MICs of yvqF/vraSR mutants are still classified as resistant (9).  447 
Despite being closely related, the RN4220 and BB270 strain sets also showed 448 
different resistance phenotypes on several non-ß-lactam antibiotics, including 449 
fosfomycin, tunicamycin, D-cycloserine and bacitracin, which should not be 450 
influenced by the presence SCCmec in BB270. Reasons for these differences, in 451 
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both intrinsic resistance profiles of the wild type strains and on the impacts of 452 
∆YvqF/∆VraS/∆VraR mutations, are currently unknown. RN4220 is known to differ 453 
from other NCTC8325-derived strains in its general global regulation (17), which may 454 
contribute to altered susceptibly profiles to some antimicrobial agents.  455 
Resistance profiling by gradient plate analysis showed that ∆YvqF/∆VraS/∆VraR 456 
mutation in S. aureus severely increased susceptibility to the detergent triton X-100. 457 
Detergents are extremely potent inducers of the S. aureus CWSS (unpublished 458 
data), and although they are known to directly damage cell membranes their 459 
induction of the CWSS is probably indirect, as triton X-100 is known to alter autolytic 460 
enzyme activities (10). In staphylococci and other gram positive bacteria triton X-100 461 
been shown to induce the release of lipoteichoic acids from the cell wall, which 462 
subsequently stimulates autolysin activities (18, 25, 37) and could thereby indirectly 463 
trigger CWSS induction. Detergent susceptibility was also shown to increase in S. 464 
mutans when liaFSR genes were deleted (45). 465 
Lysostaphin was the only inducing agent tested for which inactivation of YvqF/VraSR 466 
had no observable impact on resistance levels in either strain; some other 467 
resistances, including daptomycin, D-cycloserine and ceftobiprole, were also only 468 
marginally affected, although all four of the above agents are inducers of the CWSS 469 
(36, 47) (unpublished data). No apparent links could be drawn between the types of 470 
antibiotics or their specific targets and the impact of yvqF/vraSR inactivation on 471 
respective resistance/tolerance levels.   472 
Reasons for enhanced tolerance or increased heterogeneous resistance patterns in 473 
vraS mutants could be, as hypothesized for liaS mutants in S. mutans, that VraR is 474 
being activated to some extent in the absence of VraS. VraR was shown to be auto-475 
phosphoryated by acetyl phosphate in vitro and could therefore potentially be 476 
activated by phosphotransfer, independently of VraS in vivo, and upregulate CWSS 477 
genes to a certain extent (2, 45). VraS is also responsible for terminating the stress 478 
response signal, by acting as a VraR-specific phosphatase (2). It is therefore 479 
possible that VraR-controlled promoters could be affected differently in strains with 480 
no VraR, compared to strains with functional VraR, but no VraS or YvqF. Expression 481 
of psas016p-luc+ was substantially lower in ∆YvqF, ∆VraS and ∆VraR mutants than 482 
in the wild type, however there were small, but highly reproducible, differences in 483 
expression between these three mutant backgrounds. Reporter gene activity was ~2-484 
fold higher throughout growth in BB270∆VraS than in BB270∆VraR, indicating that 485 
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CWSS expression may be somewhat different in these two mutants. However, the 486 
reasons for these subtle changes in CWSS gene expression and their relevance to 487 
the corresponding resistance phenotypes of ∆YvqF, ∆VraS and ∆VraR mutants, 488 
requires further investigation.  489 
The role of YvqF, as a positive rather than negative modulator of VraSR signal-490 
transduction, corresponds well with the resistance phenotypes of yvqF mutants. 491 
Increased CWSS expression has been linked to increased glycopeptide resistance in 492 
GISA clinical isolates and shown to contribute to in vitro selected heterogeneous 493 
teicoplanin resistance (11, 23, 24). Therefore, if YvqF inactivation would lead to 494 
constitutive CWSS expression, as liaF deletion does in B. subtilis and S. mutans (20, 495 
45), resistance to teicoplanin should increase rather than drastically decreasing. 496 
Following this logic, the point mutations found in clinical GISA and selected by 497 
imipenem/teicoplanin step-selection (23) are likely to enhance signal transduction 498 
rather than leading to YvqF loss of function.  499 
BTH results indicated that the transmembrane protein YvqF interacted directly with 500 
VraS but not VraR and was therefore likely to be involved in sensing the unknown 501 
cell envelope stress signal responsible for triggering signal transduction, as 502 
previously suggested by Jordan et al. (20). 503 
 504 
 505 
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Table 1. Strains and plasmids 708 
Strain/plasmid  Relevant genotype/phenotype a Reference
/source 
S. aureus 
RN4220 Restriction-negative derivative of NCTC8325-4 (26) 
BB270 MRSA derivative of NCTC8325 containing an 
SCCmec type I 
(4) 
COL Early clinical MRSA isolate, CC8/ST250, 
SCCmec type I 
(15) 
RN4220∆orf1 RN4220 containing markerless deletion of orf1 
(sa1703) 
This study 
(Fig. 1) 
RN4220∆YvqF RN4220 containing yvqF mutation, truncating 
YvqF at the 5th aa 
This study 
(Fig. 1) 
RN4220∆VraS RN4220 containing vraS mutation, truncating 
VraS at the 2nd aa 
This study 
(Fig. 1) 
RN4220∆VraR RN4220 containing vraR mutation, truncating 
VraR at the 2nd aa 
This study 
(Fig. 1) 
BB270∆orf1 BB270 containing markerless deletion of orf1 
(sa1703) 
This study 
(Fig. 1) 
BB270∆YvqF BB270 containing yvqF mutation, truncating 
YvqF at the 5th aa 
This study 
(Fig. 1) 
BB270∆VraS BB270 containing vraS mutation, truncating 
VraS at the 2nd aa 
This study 
(Fig. 1) 
BB270∆VraR BB270 containing vraR mutation, truncating 
VraR at the 2nd aa 
This study 
(Fig. 1) 
E. coli 
DH5α F– φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 
endA1 hsdR17(rk–, mk+) phoA supE44 thi-1 
gyrA96 relA1λ– 
Invitrogen 
BTH101 F– cya-99 araD139 galE15 galK16 rpsL1 (Strr) 
hsdR2 mcrA1 mcrB1 
(22) 
Plasmids 
pKOR1 E. coli-S. aureus shuttle plasmid, for creating (1) 
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markerless deletions; repF (ts), cat, attP, ccdB, 
ori ColE1, bla,  Pxyl/tetO, secY570; Apr, Cmr 
pAW17 E. coli-S. aureus shuttle plasmid, ori ColE1, ori 
pAMα1, aac-aph; Kmr 
(41) 
pvra pAW17 containing entire vra operon of S. 
aureus COL; Kmr 
This study 
pvra∆YvqF pAW17 containing entire vra operon of 
BB270∆YvqF; Kmr 
This study 
pvra∆VraR pAW17 containing entire vra operon of 
BB270∆VraR; Kmr 
This study 
pBUS1 S. aureus - E. coli shuttle vector, tetL ; Tcr (41) 
pSP-luc+ Luciferase fusion plasmid, ori ColE1, bla, luc+; 
Apr 
Promega 
psas016p-luc+ pBUS1 containing sas016 promoter-luciferase 
reporter gene fusion; Tcr 
This study 
pKT25 BTH vector encoding the T25 fragment of CyaA 
upstream of the multiple cloning site;  ori p15A; 
Kmr 
(22) 
pKNT25 BTH vector encoding the T25 fragment of CyaA
 
downstream of the multiple cloning site,  ori 
p15A; Kmr 
(21) 
pUT18C BTH vector encoding the T18 fragment of CyaA 
upstream of the multiple cloning site; ori ColE1; 
Apr 
(22) 
pUT18 BTH vector encoding the T18 fragment of CyaA 
downstream of the multiple cloning site; ori 
ColE1; Apr 
(22) 
a
 Abbreviations: Strr, streptomycin resistance; Apr, ampicillin resistance; Cmr, 709 
chloramphenicol resistance; Kmr, kanamycin resistance; Tcr, tetracycline resistance710 
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Table 2. Primers used in this study 711 
Primer name Nucleotide sequence (5’-3’) a Reference 
 Construction of pKOR1 mutagenesis plasmids  
 
attB1-yvqF.upF GGGGACAAGTTTGTACAAAAAAGCAGGCTGATTCCAAGTAAGCGTGTCAT 
This study 
 
attB2-
yvqF.downR 
GGGGACCACTTTGTACAAGAAAGCTGGGTCA
TCCATGTCATCCATAAGTA This study 
 yvqF-XhoI.upR ATTTACTCGAGATATTTGTGTGTCATGTTTCG This study 
 
XhoI-stop-
yvqF.downF 
AATTTCTCGAGTGATAGATATCAACGCAAATG
TTGATC This study 
 BamHI-orf1.upR AATTTGGATCCATAGTTCATAACTATCACCTT This study 
 
BamHI-
orf1.downF AATTTGGATCCAATTATATGAACGCTGTGGCA This study 
 XhoI-vraS.upR ATTTACTCGAGGTTCATCGATAAATCACCTCTA This study 
 
XhoI-stop-
VraS.downF 
AATTTCTCGAGTGATAGCACTACATTAGAACA
ATTGGTT This study 
 
attB1-vraR.upF GGGGACAAGTTTGTACAAAAAAGCAGGCTGCTATTAATTGCATTCACATTAT 
This study 
 XhoI-vraR.upR ATTTACTCGAGCGTCATACGAATCCTCCTTAT This study 
 
XhoI-stop-
vraR.downF 
AATTTCTCGAGTGATAGATTAAAGTATTGTTTG
TGGAT 
This study 
 
attB2-
vraR.downR 
GGGGACCACTTTGTACAAGAAAGCTGGGTAA
ACGAAGCTTAAGTCAGTATTA 
This study 
Construction of complementation plasmids  
 vra.compF  AATTTGGATCCGCACATGTACTTAATTACTT  This study 
 vra.compR AATTTGGTACCCGAATATGATGAAGATAGTA  This study 
Construction of luciferase-fusion plasmid 
 
 SAS016.lucF AATTA GGTACC TGGATCACGGTGCATACAAC This study 
 SAS016.lucR AATTA CCATGG CCTATATTACCTCCTTTGCT This study 
Amplification of DIG-labelled probes 
 vraR.For ATGACGATTAAAGTATTGTT This study 
 vraR.Rev TTGAATTAAATTATGTTGGA This study 
 SAS016.For TCATACGTTCTATGTCTGAT This study 
 SAS016.Rev  GATCTATATCGTCTTGTAAT This study 
Construction of BTH plasmids 
 yvqF.pKT25F ATTAACTGCAGTGACACACAAATATATATCAA This study 
 yvqF.pUT18CF ATTAACTGCAGGACACACAAATATATATCAAC This study 
 yvqF.BTHR ATTAAGGTACCCGATAAATCACCTCTACGTC This study 
 vraS.pKT25F ATTAACTGCAGTGAACCACTACATTAGAACAA This study 
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 vraS.pUT18CF ATTAACTGCAGGAACCACTACATTAGAACAAT This study 
 vraS.BTHR ATTAAGGTACCTCGTCATACGAATCCTCCTT This study 
 vraR.pKT25F ATTAACTGCAGTGACGATTAAAGTATTGTTT This study 
 vraR.pUT18CF ATTAACTGCAGGACGATTAAAGTATTGTTTG This study 
 vraR.BTHR ATTAAGGTACCTGAATTAAATTATGTTGGAA This study 
 sigB.pKT25F ATTAACTGCAGTGGCGAAAGAGTCGAAATCA This study 
 sigB.pKT25R ATTAAGGATCCTATTGATGTGCTCGTTCTTG This study 
 rsbW.pUT18CF ATTAACTGCAGGCAATCTAAAGAAGATTTTA This study 
 rsbW.pUT18CR ATTAAGGATCCTAGCTGATTTCGACTCTTTC This study 
a Restriction sites are underlined, attB sites are in bold and introduced stop codons in 712 
italics 713 
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Table 3. MIC comparisons of vra operon mutants 714 
 715 
 OX FX IP TP a VA a BA FM DPC TM b 
RN4220 0.25 2 0.032 1 (3) 2 (4) 64 0.38 0.19 32 
RN4220∆orf1 0.25 2 0.032 1 (2) 2 (4) 64 0.5 0.19 32 
RN4220∆YvqF 0.25 2 0.032 0.38 (1) 1.5 (4) 16 0.125 0.25 16 
RN4220∆VraS 0.25 2 0.032 0.75 (3) 2 (6) 16 0.38 0.38 8 
RN4220∆VraR 0.25 2 0.032 0.125 (0.25) 1.5 (2) 12 0.125 0.19 16 
          
BB270 >256 >256 >32 1 (3) 2 (4) >256 2 0.25 >32 
BB270∆orf1 >256 >256 >32 1 (3) 2 (4) >256 2 0.25 >32 
BB270∆YvqF 96 128 8 0.094 (0.125) 1 (2) 48 0.38 0.19 32 
BB270∆VraS 96 96 16 0.5 (4) 3 (8) 48 4 0.25 32 
BB270∆VraR 96 96 8 0.094 (0.125) 1 (2) 48 0.38 0.19 32 
 716 
Abbreviations: OX, oxacillin; FX, cefoxitin; IP, imipenem; TP, teicoplanin; VA, vancomycin; BA, bacitracin; FM, fosfomycin; DPC, 717 
daptomycin; TM, tunicamycin 718 
a
 MIC values in parentheses were determined by macro-Etest (49) 719 
b
 MIC determined by microdilution 720 
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FIGURE LEGENDS 721 
 722 
Fig. 1. Map of the orf1-yvqF-vraS-vraR operon and construction of mutants. A, wild 723 
type operon structure, with the single autoregulatory promoter element indicated by 724 
an arrow (3) and the predicted transcriptional terminator (http://cmr.jcvi.org/) 725 
indicated by a stem-loop symbol. B, markerless deletion of orf1, leaving only the first 726 
3 aa’s fused in frame to the last 8 aa’s. C, YvqF was truncated by markerless 727 
insertion of an XhoI site and two in-frame stop codons after the 5th aa. D, VraS 728 
mutant, truncated by stop codons inserted after the 2nd aa. E, VraR mutant truncated 729 
by stop codons inserted after the 2nd aa.  730 
 731 
Fig. 2. S. aureus peptidoglycan synthesis and targets of cell wall active antibiotics. 732 
Inhibition of enzymatic reactions is indicated by blocked arrows; inhibition of cell wall 733 
synthesis by binding of antibiotics to peptidoglycan precursors is indicated by half-734 
moon symbols; pentaglycine-bridge cleavage by lysostaphin and membrane 735 
disruption/depolarization by daptomycin, are indicated by arrows. (Adapted from 736 
(31)). 737 
 738 
Fig. 3. Antibiotic resistance profiles of vra operon mutants. A, population analysis 739 
profiles of BB270 and its ∆orf1, ∆YvqF, ∆VraS and ∆VraR mutants. B, growth 740 
phenotypes of RN4220 and BB270 compared to their respective vra operon mutants 741 
on antibiotic gradient plates. Antibiotic and triton X-100 concentration gradients are 742 
indicated.  743 
 744 
Fig. 4. Trans-complementation of vra operon mutants. A, teicoplanin gradient plates 745 
comparing the resistance levels of wild type and mutant strains, containing either the 746 
empty vector pAW17 or the complementing plasmid pvra. B, schematic 747 
representation of trans-complementation plasmids pvra, containing the wild type vra 748 
operon; pvra∆YvqF, containing the vra operon from BB270∆YvqF; and pvra∆VraR, 749 
containing the vra operon from BB270∆VraR. C, teicoplanin gradient plates showing 750 
trans-complementation of BB270∆YvqF with pvra∆VraR; BB270∆VraS with 751 
pvra∆YvqF and pvra∆VraR; and BB270∆VraR with pvra∆YvqF. 752 
 753 
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Fig. 5. Induction of CWSS transcripts in vra operon mutants. A, transcriptional 754 
profiles of sas016 and the vra operon in BB270 and its four vra operon mutants. RNA 755 
was harvested from strains containing either the empty plasmid pAW17 or the trans-756 
complementation plasmid pvra, both before and after vancomycin induction. Ethidium 757 
bromide stained 16S rRNA bands are shown below Northern blots as an indication of 758 
RNA loading. B, Levels of luciferase activity from psas016p-luc+ in both uninduced 759 
and vancomycin-induced cultures of BB270 and its ∆orf1, ∆YvqF, ∆VraS and ∆VraR 760 
mutants. All values shown represent the mean ± SD obtained from two independent 761 
cultures. C, profiles of luciferase activity over growth in BB270∆YvqF, BB270∆VraS 762 
and BB270∆VraR, containing psas016p-luc+. All values shown represent the mean ± 763 
SD obtained from three independent cultures.  764 
 765 
Fig. 6. BTH analysis YvqF, VraS and VraR. A, scheme of VraSR signal-transduction. 766 
Cell wall stress triggers VraS to activate VraR by phosphotransfer. Activated VraR 767 
controls a large regulon in addition to autoregulating its own expression. VraR is also 768 
deactivated by VraS-specific dephosphorylation (2, 19) (adapted from (31)). B, 769 
potential protein-protein interactions between the transmembrane protein YvqF and 770 
VraS/VraR. C, Phenotypes of co-transformants containing combinations of BTH 771 
fusion-protein pairs, on minimal medium containing lactose as a sole carbon source 772 
and Xgal. Positive interactions are indicated by growth and blue pigmentation.  Three 773 
clones were tested from each co-transformation and negative and positive controls 774 
were included for phenotypic comparison. D, ß-galactosidase activity of the BTH 775 
clones shown above, measured by ONPG cleavage assays. Values given indicate 776 
the mean ± SD expression of the three clones.    777 
Figure 1
XhoI Stop
XhoI Stop Stop
vraS vraRyvqForf1
XhoI
yvqF
ATG ACA CAC AAA TAT CTC GAG TGA TAG ATA...
ATG ACA CAC AAA TAT ATA...wild type:
mutant:
Stop Stop
vraS
ATG AAC CTC GAG TGA TAG CAC ...
ATG AAC CAC ...wild type:
mutant:
A
B
C
D
vraR
ATG ACG CTC GAG TGA TAG ATT ...
ATG ACG ATT …wild type:
mutant:
E
1 kb
Stop
Figure 2
L-Ala
UDP UDP
D-Glu
UDP
L-Lys
UDP
D-Ala2
D-Ala
UDP
UDP-
GlcNAc tRNAGly 2 x 
tRNAGly
2 x 
tRNAGly
Transpeptidation
ß-lactams
(PBPs)
glycopeptides
(D-ala-D-ala)
Transglycosylation
moenomycin
(flavomycin)(lipid II)
ramoplanin
bacitracin
Lipid carrier recycling
(pyrophosphorylase)
(D-alanine racemase,
D-alanine ligase)
D-cycloserine
fosfomycin
(MurA) (MraY)
tunicamycin
K+
K+
K+
daptomycin
Membrane depolarization
lysostaphin
Pentaglycine crosslinking bridge
CYTOPLASM
EXOPLASM
MEMBRANE
UDP-
GlcNAc
UDP
UDP-
MurNAc
L-Ala
Figure 3
BB270
BB270∆orf1
BB270∆YvqF
BB270∆VraS
BB270∆VraR
teicoplanin
0
2
4
6
8
10
0 0.125 0.5 2 8
0 0.0625 0.125 0.25 0.5 1
0
2
4
6
8
10
daptomycin
cf
u
/m
l (l
o
g 1
0)
A
0 0.0625 0.25 1 4
0
2
4
6
8
10
flavomycin
cf
u
/m
l (l
o
g 1
0)
0 0.25 0.5 1 2 4
0
2
4
6
8
10
vancomycin
cf
u
/m
l (l
o
g 1
0)
0
2
4
6
8
10
0 1 10 100 1000
oxacillin
cf
u
/m
l (l
o
g 1
0)
cf
u
/m
l (l
o
g 1
0)
B
WT
∆orf1
∆YvqF
∆VraS
∆VraR
WT
∆orf1
∆YvqF
∆VraS
∆VraR
WT
∆orf1
∆YvqF
∆VraS
∆VraR
WT
∆orf1
∆YvqF
∆VraS
∆VraR
WT
∆orf1
∆YvqF
∆VraS
∆VraR
RN4220 BB270
triton X-100 (% V/V)0 0.5 triton X-100 (% V/V)0 0.5
ramoplanin (µg/ml)0 0.5 ramoplanin (µg/ml)0 0.5
D-cycloserine (µg/ml)0 64 D-cycloserine (µg/ml)0 64
ceftobiprole (µg/ml)0 2 ceftobiprole (µg/ml)0 2
lysostaphin (µg/ml)0 0.25 lysostaphin (µg/ml)0 0.25
Figure 4
RN4220 BB270
WT
∆orf1
∆YvqF
∆VraS
∆VraR
pAW17
pvra
pAW17
pvra
pAW17
pvra
pAW17
pvra
pAW17
pvra
0 4teicoplanin (µg/ml) 0 4teicoplanin (µg/ml)
A
B
0 4teicoplanin (µg/ml)
WT pAW17
∆YvqF pAW17
∆YvqF pvra∆VraR
WT pAW17
∆VraR pAW17
∆VraR pvra∆YvqF
WT pAW17
∆VraS pAW17
∆VraS pvra∆YvqF
∆VraS pvra∆VraR
vraS vraRyvqForf1
kanR
pvra∆YvqF
kanR
vraS vraRyvqForf1
pvra∆VraR
vraS vraRyvqForf1
kanR
pvra
C BB270
Figure 5
- + - + - + - + - + - + - + - + - + - +
sas016
vraR
BB
27
0
∆
o
rf1
∆
Yv
qF
∆
Vr
a
S
∆
Vr
a
R
BB
27
0
∆
o
rf1
∆
Yv
qF
∆
Vr
a
S
∆
Vr
a
R
+ pAW17 + pvraA
0
200
400
6000
8000
10000
12000
BB270 ∆YvqF ∆VraS ∆VraR
Uninduced
Induced
Lu
ci
fe
ra
se
a
ct
ivi
ty
 
(R
LU
)
B
∆orf1
C
0
40
80
120
160
200
0.1
1
10
0 100 200 300 400 500 600
BB270∆YvqF
BB270∆VraS
BB270∆VraR
Lu
ci
fe
ra
se
a
ct
ivi
ty
 
(R
LU
)
O
D
 
(lo
g 1
0)
Time (min)
Figure 6
P
YvqF
N
C
VraS
VraR
Active 
(dimerised) VraR
Inactive 
VraR
Vra
R
B
?
?
??
P
N
PVraR
Cell wall stress
P
P
VraR
vraS vraR
VraS
(phosphatase)
Multiple 
target 
genes
orf1 yvqF
A
VraS
(kinase)
P
VraR-T18
T18-VraR
VraS-T18
T18-VraS
YvqF-T18
T18-YvqF
VraR-T25T25-VraRT25-VraST25-YvqF
Neg. Pos.
C
0
1000
2000
3000
4000
T25-YvqF T25-VraS T25-VraR
ß-
ga
l a
ct
iv
ity
 
(M
U
)
T1
8-
Yv
qF
Yv
qF
-
T1
8
T1
8-
Vr
aS
Vr
aS
-
T1
8
T1
8-
Vr
aR
Vr
aR
-
T1
8
T1
8-
Yv
qF
Yv
qF
-
T1
8
T1
8-
Vr
aS
Vr
aS
-
T1
8
T1
8-
Vr
aR
Vr
aR
-
T1
8
T1
8-
Yv
qF
Yv
qF
-
T1
8
T1
8-
Vr
aS
Vr
aS
-
T1
8
T1
8-
Vr
aR
Vr
aR
-
T1
8
T1
8-
Yv
qF
Yv
qF
-
T1
8
T1
8-
Vr
aS
Vr
aS
-
T1
8
T1
8-
Vr
aR
Vr
aR
-
T1
8
Ne
g.
 
D VraR-T25
Po
s.
 
P
P
